Member Info for Qd22

Aixtron in Germany supply our MOCVD machines. My biggest faller today, but they report a 9 month 39% order increase as follows:

"AIXTRON SE (FSE: AIXA) got off to a successful start in the second half of 2020. Above all, the high demand from the application markets of gallium nitride power electronics and laser technology for optical data transmission and for 3D sensor technology enabled strong business development in the third quarter.
AIXTRON SE, one of the world's leading providers of deposition systems for the semiconductor industry, acquired orders with a volume of EUR 209.3 million from January 1 to September 30 . The special equipment manufacturer has thus increased the order volume in the corresponding period of the previous year by 39%."
https://www.aixtron.com/de/presse/presseinformationen/AIXTRON%20im%20Jahresendspurt%20/%20Deutlich%20h%C3%B6here%20Wachstumsdynamik%20im%20dritten%20Quartal%20/%20Kr%C3%A4ftiges%20Auftragsplus%20von%2039%25%20/%20Weiter%20gestiegene%20Umsatzdynamik%20/%20Unver%C3%A4ndert%20hohe%20F%26E-Aktivit%C3%A4ten%20/%20Progno_n1584

If that comes up in German you can go into English on the homepage. Seems to me any alternative technologies are way behind for now? I wonder if IQE has been buying.

There is a big backlog in supply, increased by 51%, and it takes a long time (and a lot of expertise I think) to get them producing to the necessary standard once on site. IQE is up and running and has decades worth of that expertise.

If I can find some money maybe I'll top them up, but do you agree it bodes well for us?

Thanks

PS The 2015 to 2020 agreement with Solvay would have given them just the time period to build and commission their own planned 63,000 cubic metre plant, meanwhile through the offtake agreement building market share in their exclusive European territories. It looks to me like AXS and Solvay agreed to split Europe between them but I have no expertise in these things and may be completely barking up the wrong tree. Does anyone with more expertise and experience get this thing better than I do?

The 1st post on this board! 7th June 07: "Accsys is in this weeks Shares magazine in the cover story 25 Best Aim shares"

Cover story in '07! A few years later spindok was saying "We need a ramper!" Love that comment. Is the post still vacant??

I sold out, very unhappily, 5 years ago, very concerned about opacity and what we were not being told. I thought, and still think, they were hiding a ginormous mess up - probably with licences, worldwide. They lost a case against Diamond Wood China and had the costs awarded against them, and I had questions in the same area about their agreements with Solvay in Europe (RNS 26 November 2015).

"Solvay will purchase a minimum 76,000 cubic metres of Accoya from the Arnhem plant over the period from 2016 to 2020 (the "offtake commitment") and as a result of the increased manufacturing capacity in Arnhem and consequent greater sales capacity, under the new agreement Solvay will review the optimal timing to construct its 63,000 cubic metres Accoya manufacturing plant."

"The licence agreement covering Europe has been amended to provide increased royalties to Accsys and the return to Accsys of the selling rights for 20 European countries."

Had they reached an impasse and Solvay agreed some kind of deal to split the pie and to hold fire on its plant? "Accsys will provide sales and marketing services to Solvay on agreed terms in respect of Solvay's exclusive European territories." It is - above - SOLVAY'S 63,000 manufacturing plant whose construction was to be reviewed, and they have exclusive European territories.

NB the offtake agreement ends this year, 2020 - but it doesn't give an exact date. So might our revenue drop off??

In March 2018 I was under the impression they had bought Diamond Wood China, but I can't see where I got that from. Anyone spot it? That would be important because under the judgement from 2014 the licence was to continue: "In July the Company reported that the Tribunal delivered a ruling (the 'Ruling') that, in response to Diamond Wood's claim for damages in excess of €100 million, Diamond Wood can only claim for limited damages, if any, up to a maximum of €250,000. However, the Tribunal also ruled that the licence agreement between the two parties is to continue. The Tribunal has now issued a final award in respect of costs relating to the Ruling which are payable to Diamond Wood, being approximately £1.6m."

Well, I've talked myself out of spindok's job offer! But actually I'm now interested in getting back in, in spite of the concerns above. One way or another they appear to be sorting themselves out. Still opaquely, to my mind. But there is product, demand, capacity coming online, and there simply must be a way to market now or they wouldn't be doing what they are doing. But I'd love to know the actual story.

Big jump today, for no apparent reason. Hoping for my sake it pulls back so I can get in. ATB, all. Hope all this info is useful.

Pardon me, finally found it: a product of Celare, "CELARE established in May 2012 as a subsidiary of BATM group. BATM develops and manufactures network switching and routing equipment and systems for the last 20 years targeted mainly for Telecom, utilities and defense markets. BATM offers its customers a diversified array of innovative high speed network access and solutions.
CELARE is the Cyber arm of BATM bringing DPI based network perimeter monitoring solutions with integrated Big Data security analytics and threat detection, helping security professionals to better visibility of their networks."

https://celarenet.com/?page_id=122

What is this Osaka? Is it anything to do with BATM, as I can't find it?

"The Group is pleased to report that trading for the first half of the current financial year has been ahead of our COVID-19-revised ("C-19") management forecasts. There has been month-on-month improvement in operating profit and cash since the start of the financial year with September moving into profit.

Whilst the C-19 situation remains difficult to predict, the Group is in a robust financial and operating position to navigate FY2021 and continue the solid momentum that was building prior to C-19 and deliver on the exciting growth opportunities that we see ahead of us.

James Dickson, Chairman of Vianet, commented:

"Having seen a month-on-month improvement in operating profit and cash since the start of the financial year, Vianet remains in good shape to come through the C-19 crisis and emerge strongly.

"However, we once again find ourselves in uncharted waters alongside our hospitality sector customers following the government's announcement of further new measures over the past two weeks."

Sounds good in general, and promising for the long term, but vulnerable to the 2nd wave.

Names please DD77.....

PS. The list of institutional shareholders has some pretty good names IMV.

I can't see that. (Which means it probably will!)

So stupid, I can't actually remember why I bought here, and was looking today at selling. But the directors tend to be active in buying and selling, sold at 98p, and recently bought in again. After the results in September, when they were allowed, so not long back. This was the CEO and the FD: big fish, in this small pond.

Other plus points are the Quality rating on Stockopedia (I'm not great at analysis for myself), and it's very cheap, with a good divi.

I'm holding, but somewhat unhappily.

If it's big in the non-profit sector others in that sector with less budget to research may follow along.

They must have been negotiating this contract in September, so it may be why - or part of why - they had such high hopes for October. More to come?? It's great that it's FDA cleared as well as CE marked.

PS Libero, why do you see it as undervalued? I can't do that kind of stuff for tuppence, so I pay for Stockopedia, which rates it as quite expensive. But I'm not so bothered by that as by the quality and momentum factors, for which it gets high ratings on both. [They rate companies by Quality, Value and Momentum measures, making a combined rating of those 3 scores. But from what I can see, over the longest term they can give, Quality and Momentum alone give a slightly better performance.]

2nd October: "...trading in October is expected to suggest a strong Q4 performance..."

Interesting phraseology that: literally they are projecting good October trading, from which they further project a good Q4! But with an extra update being, um, projected in early November - just one month on - it looks like they are expecting great things of October.

Which looks like now is a great time to be in. With the vaccine date being pushed out and further out and this 2nd wave being far more serious than governments expected (otherwise they would have held the lockdown for a further couple of weeks in the summer to knock it right down) I suspect the researchers are getting what they ask for - which means virus samples, and EKF, among other things.

Any thoughts?

bhargav, you've kept the faith for a long, long time, given that it appears to be your only holding. Impressive!

I hope for you - as well as myself! - that it goes very, very well here. And thanks for your continued input, you know this share as well as anyone.

You were right. CFO gone, CEO gone, auditors gone, cash hole by the look of it, my money gone, and the previous auditors confirm there was nothing shareholders needed to be aware of. Really???

String of implied negatives – none of which are substantiated.

I like that last sentence:

“ For those investors who feel they might have missed the boat a little on the surge in the gold miners, this is a perfect and relatively safe way to gain leverage to the gold price as well as a well-executed organic expansion strategy.”

There will be many who are thinking that, or at least “I should have got in earlier”. The share price being down year-on-year is a simple clear point. We all know what’s happened to the price of gold.

Simon Thomson recommendation again today, and Pelatro. Pelatro up 16%, BVC just 3.5. I've seen people diss ST, but my profits from him - including here - have paid for the mag many times over. Just don't follow the other guys! Pardon me, Chris Dillow is useful, John Rosier, and John Baron if you're into investment trusts. It's the main mag tips that have been disastrous in my experience.

10,000 tests a month equates to 333 a day.

Useful within the hospital context no doubt - especially if your machine is sat there idling doing nothing else. Which it won't be. But the automation side WILL be really useful.

I'm in here, but that figure doesn't get my juices going too much.